Cargando…

Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

BACKGROUND: Targeting immune checkpoints represents an immense breakthrough in cancer therapeutics. The prognostic value of hemoglobin (Hb) has been investigated in many malignancies including non-small cell lung cancer (NSCLC). However, the prognostic impact of pretreatment Hb count for immune chec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhibo, Zhang, Fan, Yuan, Fang, Li, Ye, Ma, Junxun, Ou, Qiuxiang, Liu, Zhefeng, Yang, Bo, Wang, Lijie, Tao, Haitao, Zhang, Sujie, Li, Xiaoyan, Zhi, Xiaoyu, Ge, Xiangwei, Bao, Hua, Wu, Xue, Hu, Yi, Wang, Jinliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649885/ https://www.ncbi.nlm.nih.gov/pubmed/33224276 http://dx.doi.org/10.1177/1758835920970049

Ejemplares similares

Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zhang, Zhibo, et al.
Publicado: (2020)

Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors
por: Chen, Shixue, et al.
Publicado: (2020)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
por: Wu, Zhaozhen, et al.
Publicado: (2021)

Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort
por: Sun, Danyang, et al.
Publicado: (2018)

Immunotherapy beyond progression in patients with advanced non-small cell lung cancer
por: Ge, Xiangwei, et al.
Publicado: (2020)

Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors
por: Chen, Shixue, et al.
Publicado: (2021)

Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
por: Chen, Shixue, et al.
Publicado: (2021)

First‐line PD‐1/PD‐L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non‐squamous non‐small cell lung cancer: A Bayesian network meta‐analysis of randomized controlled trials
por: Zhai, Jinzhao, et al.
Publicado: (2022)

Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
por: Cui, Pengfei, et al.
Publicado: (2020)

Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting
por: Wu, Zhaozhen, et al.
Publicado: (2021)

Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis
por: Zhang, Zhibo, et al.
Publicado: (2019)

Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade
por: Shang, Jin, et al.
Publicado: (2021)

Decreased expression of RASSF10 correlates with poor prognosis in patients with colorectal cancer
por: Ma, Junxun, et al.
Publicado: (2017)

Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis
por: Cui, Pengfei, et al.
Publicado: (2023)

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
por: Li, Ye, et al.
Publicado: (2020)

Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study
por: Li, Xiaoyan, et al.
Publicado: (2022)

Swainsonine Inhibits Invasion and the EMT Process in Esophageal Carcinoma Cells by Targeting Twist1
por: Ma, Junxun, et al.
Publicado: (2018)

Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy
por: Li, Lingling, et al.
Publicado: (2021)

Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer
por: Zhang, Fan, et al.
Publicado: (2020)

Pretreatment Hematocrit Is Superior to Hemoglobin as a Prognostic Factor for Triple Negative Breast Cancer
por: Chen, Bo, et al.
Publicado: (2016)

Pretreatment Hemoglobin Level Is an Independent Prognostic Factor in Patients with Lung Adenocarcinoma
por: Zhang, Yue-Hua, et al.
Publicado: (2018)

Efficacy of Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural or Peritoneal Effusions
por: ZHANG, Xin, et al.
Publicado: (2013)

Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma
por: Sun, Tao, et al.
Publicado: (2023)

Glycosylated Hemoglobin as a Predictor of Sepsis and All-Cause Mortality in Trauma Patients
por: Guo, Feng, et al.
Publicado: (2021)

Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases
por: Wang, Chunyu, et al.
Publicado: (2023)

Predictive value of DOT1L mutations for clinical outcomes in non‐small‐cell lung cancer patients receiving immune checkpoint inhibitor therapy
por: Guo, Tianxing, et al.
Publicado: (2023)

Gut mycobiome as a potential non-invasive tool in early detection of lung adenocarcinoma: a cross-sectional study
por: Liu, Qingyan, et al.
Publicado: (2023)

Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer
por: Shin, Na-Ri, et al.
Publicado: (2014)

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China
por: Yang, Wenyu, et al.
Publicado: (2023)

CT-Based Peritumoral and Intratumoral Radiomics as Pretreatment Predictors of Atypical Responses to Immune Checkpoint Inhibitor Across Tumor Types: A Preliminary Multicenter Study
por: He, Shuai, et al.
Publicado: (2021)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
por: Gao, Ming, et al.
Publicado: (2023)

XRCC2 Polymorphisms and Environmental Factors Predict High Risk of Colorectal Cancer
por: Wang, Lijie, et al.
Publicado: (2018)

Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer
por: Lee, Chung-Shien, et al.
Publicado: (2020)

Correlation of Pretreatment Hemoglobin and Platelet Counts with Clinicopathological Features in Colorectal Cancer in Saudi Population
por: Al-Saeed, Eyad F., et al.
Publicado: (2014)

Low Hematocrit Is a Strong Predictor of Poor Prognosis in Lung Cancer Patients
por: Zhang, Xin, et al.
Publicado: (2018)

Structural optimization and prospect of constructing hemoglobin oxygen carriers based on hemoglobin
por: Ma, Yuexiang, et al.
Publicado: (2023)

Is Hemoglobin Concentration a Linear Predictor of Mortality in Older Adults From Chinese Longevity Regions?
por: Ren, Jiaojiao, et al.
Publicado: (2021)

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma
por: Li, Liu, et al.
Publicado: (2023)

Correlation of Pretreatment Hemoglobin and Platelet Counts with Clinicopathological Features in Colorectal Cancer in Saudi Population: Erratum
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vh1sg46d301t60ehg033mff0dd